VBWG Online CME Program

 Contemporary, Challenging, and Controversial Issues in Atrial Fibrillation Management
  Presented By:

Michael D. Ezekowitz, MBChB, DPhil

Vice President Clinical Research, Main Line Hospitals
Professor of Medicine, Jefferson Medical College
Philadelphia, PA

Peter J. Kudenchuk, MD

Professor of Medicine
Director of Arrhythmia Services
University of Washington Medical Center
Seattle, WA

Edward P. Gerstenfeld, MD, MS

Chief, Cardiac Electrophysiology & Arrhythmia Service
Associate Professor of Medicine
University of California San Francisco Medical Center
San Francisco, CA

  Program Description:This CME activity consists of an educational component (ie, slides, audio lecture, newsletter) in an electronic format, followed by an online post-test. Estimated time to complete this activity, including review of materials, is 60 minutes.
  General Information:Requirements for Successful Completion:

  • This CME activity consists of an educational component (ie, slides, audio lecture, newsletter) in an electronic format, which is followed by an online post-test.
  • There is no fee to participate in this CME activity or to receive CME credit.
  • Certificates are awarded upon successful completion (80% proficiency) of the post-test.
  • In order to receive credit, participants must view the presentation in its entirety.
Media: Internet
Release Date:    April 6, 2012
Expiration Date:  April 6, 2014
  Target Audience:Clinical Cardiologists, Electrophysiologists, Nurse Practitioners, Physician Assistants, Pharmacists, Nurses, and other healthcare professionals involved in the care of patients with atrial fibrillation.
  Program Overview:This online CME activity is based on Contemporary, Challenging, and Controversial Issues in Atrial Fibrillation Management: A Novel, Interactive, VBWG CME Activity held on Feb. 11, 2012 in Seattle, WA. Designed to elevate the practice of AF management, prestigious faculty experts engage clinicians in understanding and synthesizing the latest data and guideline recommendations on rate and rhythm control and stroke prevention.
  Learning Objectives:
  1. Recognize the clinical consequences of AF, and the recent guideline recommended treatment strategies to minimize mortality, morbidity, and stroke risk
  2. Define the challenges and benefits associated with rate or rhythm control strategies in patients with AF and the therapeutic options for each strategy
  3. Discuss how the recent ACC/AHA/HRS and ESC guidelines for AF management can be used to develop individualized care plans to optimize patient outcomes
  Faculty Disclosure:

The University of Florida College of Medicine Continuing Medical Education has a policy to ensure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored educational programs. All individuals involved in any program sponsored by the University of Florida College of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. All conflicts are resolved prior to the activity. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of facts. It remains for the audience to determine whether the speaker’s outside interests may reflect a possible bias in either the exposition or the conclusions presented.

Michael D. Ezekowitz, MBChB, DPhil: Consultant: ARYx Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Gilead, Johnson & Johnson, Medtronic, Inc., Merck & Co., Inc., Pfizer Inc., Portola Pharmaceuticals, Inc., Sanofi US

Edward P. Gerstenfeld, MD, MS: Grant/Research Support: Biosense Webster, Inc., St. Jude Medical, Inc.

Peter J. Kudenchuk, MD: Speaker Bureau for Educational Lectures for Medical Professionals: Boehringer Ingelheim, Sanofi US; Stock Shareholder (modest): Sanofi US
  Continuing Medical Education Credit:
  The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  The University of Florida College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  This continuing education activity was planned in accordance with the ACCME essentials and reviewed by Carl J. Pepine, MD, Program Chair.
  Click here for disclosure and disclaimer information
  Commercial Support:

This independent educational activity is supported by a grant from Sanofi US.
  System Requirements:In order to view the presentation, your computer must have a media player such as Windows Media Player, Quicktime, or RealOne.
  CME Contact:For any questions regarding this CME activity, please contact the Office of Continuing Medical Education at 352-733-0064.

Privacy and Confidentiality Policy
VBWG Online CME © 2018Medtelligence, LLC.All Rights Reserved.
Questions or Comments: info@vbwg.org
close window